In an adult patient with focal or generalized seizures, how do levetiracetam and brivaracetam compare in terms of efficacy, dosing, safety, and side‑effect profile?

Levetiracetam vs Brivaracetam: Comparative Analysis

Levetiracetam and brivaracetam demonstrate similar efficacy for focal and generalized seizures, with approximately 45-47% seizure cessation rates in status epilepticus, but brivaracetam offers a superior tolerability profile with fewer psychiatric adverse effects, making it the preferred choice when psychiatric side effects are a concern or when switching from levetiracetam due to tolerability issues. 1

Efficacy Comparison

Status Epilepticus (Second-Line Treatment)

Both agents show equivalent efficacy as second-line treatment after benzodiazepine failure:

• Levetiracetam: 47% seizure cessation at 60 minutes 1
• Brivaracetam: No direct comparison data in status epilepticus guidelines, but systematic reviews show 56% overall seizure cessation rate 2
• The 2024 ACEP guidelines provide Level A evidence that levetiracetam, fosphenytoin, and valproate may be used with similar efficacy for benzodiazepine-refractory status epilepticus 1

Focal Seizures (Adjunctive Therapy)

Meta-analytic evidence suggests levetiracetam may have slightly higher efficacy:

• Indirect comparison shows most risk ratios >1 favoring levetiracetam for 50% responder rates 3
• However, the differences are not statistically significant across various dose levels 3
• A 2026 phase III trial in Chinese patients showed brivaracetam 200 mg/day achieved 40.67% reduction in seizure frequency with 48.89% responder rate 4

Monotherapy Outcomes

Real-world data from 2026 shows brivaracetam monotherapy achieved:

• 44% seizure freedom (≥6 consecutive months) at any time during follow-up 5
• 79% responder rate at 6 months 5
• Particularly favorable when converted from levetiracetam: 52% seizure freedom at 6 months 5

Dosing

Levetiracetam 6

Adults (≥16 years):

• Starting dose: 1000 mg/day (500 mg BID)
• Titration: Increase by 1000 mg/day every 2 weeks
• Maximum: 3000 mg/day
• Pediatric (4-16 years): Start 20 mg/kg/day (10 mg/kg BID), increase by 20 mg/kg every 2 weeks to 60 mg/kg/day

Brivaracetam 7

Adults (≥16 years):

• Starting dose: 50 mg BID (100 mg/day)
• Range: 25-100 mg BID (50-200 mg/day)
• Pediatric (1 month to <16 years): Weight-based dosing
• Hepatic impairment: Dose reduction required for all stages (unlike levetiracetam)

Critical dosing consideration: Brivaracetam requires dose adjustment in hepatic impairment, while levetiracetam requires adjustment in renal impairment 7.

Safety and Side Effect Profile

Psychiatric Adverse Events

Brivaracetam demonstrates superior psychiatric tolerability:

• Levetiracetam associated with significantly higher irritability (OR 2.55,95% CI 1.41-4.63) 8
• When switching from levetiracetam to brivaracetam, 79.6% experienced improvement in tolerability 5
• Psychiatric side effects decreased when switching from levetiracetam to brivaracetam 9
• The 2021 EANO-ESMO guidelines note that psychiatric side effects with levetiracetam "remain a concern" 10

Common Adverse Events

Levetiracetam 8:

• Somnolence (OR 1.80,95% CI 1.41-2.30)
• Irritability (OR 2.55,95% CI 1.41-4.63)
• Asthenia (OR 1.71,95% CI 1.15-2.54)
• Headache, fatigue

Brivaracetam 8, 4:

• Somnolence (OR 1.86,95% CI 1.33-2.61)
• Dizziness (OR 1.75,95% CI 1.24-2.46) - more common than levetiracetam 3, 8
• Fatigue (OR 2.14,95% CI 1.43-3.20)
• Nausea

Cardiovascular Safety

In status epilepticus treatment 1:

• Levetiracetam: 0.7% life-threatening hypotension, 0.7% arrhythmias
• Fosphenytoin: 3.2% life-threatening hypotension (numerically higher but not statistically significant)
• Levetiracetam shows favorable cardiovascular profile

Tolerability in Real-World Practice

A 2026 study showed when switching to brivaracetam monotherapy 5:

• 92% of pre-existing adverse events resolved
• Only 1.9% experienced newly emerging adverse events
• 22.4% overall adverse event rate (predominantly mild psychiatric or sleep-related)

Drug Interactions

Levetiracetam

• Minimal drug interactions - major advantage 10
• No enzyme induction
• Preferred in brain tumor patients due to lack of interactions with chemotherapy and targeted agents 10

Brivaracetam 7

• Rifampin: Decreases brivaracetam concentrations; dose increase recommended
• Carbamazepine: Increases carbamazepine metabolite exposure; may need carbamazepine dose reduction
• Phenytoin: Can increase phenytoin levels; monitor phenytoin concentrations
• Levetiracetam: No added therapeutic benefit when co-administered 7

Critical interaction: Brivaracetam should not be co-administered with levetiracetam as it provides no additional benefit 7.

Clinical Decision Algorithm

When to Choose Levetiracetam:

1. First-line adjunctive therapy for focal or generalized seizures 10
2. Brain tumor-related seizures (preferred due to minimal drug interactions) 10
3. Status epilepticus (Level A evidence as second-line agent) 1
4. Renal impairment (dose adjustment straightforward)
5. When dizziness is a concern (lower incidence than brivaracetam)

When to Choose Brivaracetam:

1. Levetiracetam-induced psychiatric adverse effects (irritability, aggression, depression) 9, 5
2. Patients requiring better psychiatric tolerability from the start 8
3. Hepatic impairment (approved dosing adjustments available) 7
4. Monotherapy consideration in selected patients (real-world evidence supports) 5
5. When switching from levetiracetam due to tolerability (52% seizure freedom rate) 5

When to Switch from Levetiracetam to Brivaracetam:

• Psychiatric side effects (irritability, aggression, mood changes)
• Behavioral adverse events despite adequate seizure control
• Expected outcome: 79.6% improvement in tolerability, 52% seizure freedom at 6 months 5

Common Pitfalls

1. Co-prescribing levetiracetam and brivaracetam: Provides no added benefit and increases cost 7

2. Ignoring hepatic function with brivaracetam: Unlike levetiracetam, brivaracetam requires dose adjustment in all stages of hepatic impairment 7

3. Overlooking drug interactions with brivaracetam: Monitor for interactions with rifampin, carbamazepine, and phenytoin 7

4. Dismissing psychiatric symptoms on levetiracetam: These are significant and well-documented; switching to brivaracetam often resolves them 9, 5

5. Assuming brivaracetam is always superior: Efficacy is similar, and levetiracetam has more extensive evidence base and lower cost in most settings 3, 8

6. Inadequate dosing: Both drugs require titration to effective doses (levetiracetam up to 3000 mg/day, brivaracetam up to 200 mg/day) 7, 6